Alnylam Lays Out 2015 Goals

Xconomy Boston — 

Alnylam Pharmaceuticals (NASDAQ: ALNY), the Cambridge, MA-based developer of RNA-interference drugs, said today it has set a goal of moving five RNAi development programs into advanced clinical testing by 2015. Alnylam also named a new drug candidate for refractory anemia, which it hopes to move into clinical trials in 2012. The company said it hopes to form new partnerships, and that it expects to finish this year with more than $275 million of cash and investments left in the bank—meaning that it expects to reach its goals while burning less than $70 million of its existing cash reserves.